Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program

Introduction: In recent decades, hemophilia A treatment has been focused on body weight, without taking pharmacokinetic parameters into account. Previous research has shown that the individual pharmacokinetic response is more effective in predicting the required dose of clotting factor. We want to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Samuel sarmiento Doncel, Gina Alejandra Diaz Mosquera, Javier Mauricio Cortes, Nelson Ramirez, Francisco Javier Meza, Carol Agudelo Rico
Formato:	article
Lenguaje:	EN
Publicado:	PAGEPress Publications 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/a5ae7a1c44ac4daba6f5389cbcdbe17d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5ae7a1c44ac4daba6f5389cbcdbe17d
record_format	dspace
spelling	oai:doaj.org-article:a5ae7a1c44ac4daba6f5389cbcdbe17d2021-11-26T14:38:48ZImpact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program10.4081/hr.2021.89042038-83222038-8330https://doaj.org/article/a5ae7a1c44ac4daba6f5389cbcdbe17d2021-11-01T00:00:00Zhttps://www.pagepress.org/journals/index.php/hr/article/view/8904https://doaj.org/toc/2038-8322https://doaj.org/toc/2038-8330 Introduction: In recent decades, hemophilia A treatment has been focused on body weight, without taking pharmacokinetic parameters into account. Previous research has shown that the individual pharmacokinetic response is more effective in predicting the required dose of clotting factor. We want to evaluate the impact on reducing the frequency of bleeding in patients treated with recombinant factor VIII, based on a personalized comprehensive management program. Objective: Our aim was to compare the results of a standard comprehensive treatment program (stage I) vs. a personalized pharmacokinetic - based treatment program (stage II) in a cohort of 60 patients with severe hemophilia without inhibitors. Results:The median age was 15.5 years (3 - 68). The ABR was 1.03 (62 episodes) in the first stage and 0.58 (35 episodes) in the second one, (p = 0.004). By type of bleeding, the impact of the intervention differs significantly in spontaneous bleeding (p = 0.007) and a 73% reduction in the first stage. There were no significant differences in traumatic bleeding. Conclusions: The use of pharmacokinetics for personalized dosing of patients with severe hemophilia A, significantly reduces ABR and spontaneous bleeding, improving the patient's quality of life and costs for the health system. Samuel sarmiento DoncelGina Alejandra Diaz MosqueraJavier Mauricio Cortes Nelson RamirezFrancisco Javier MezaCarol Agudelo RicoPAGEPress PublicationsarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology Reports, Vol 13, Iss 4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Samuel sarmiento Doncel Gina Alejandra Diaz Mosquera Javier Mauricio Cortes Nelson Ramirez Francisco Javier Meza Carol Agudelo Rico Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
description	Introduction: In recent decades, hemophilia A treatment has been focused on body weight, without taking pharmacokinetic parameters into account. Previous research has shown that the individual pharmacokinetic response is more effective in predicting the required dose of clotting factor. We want to evaluate the impact on reducing the frequency of bleeding in patients treated with recombinant factor VIII, based on a personalized comprehensive management program. Objective: Our aim was to compare the results of a standard comprehensive treatment program (stage I) vs. a personalized pharmacokinetic - based treatment program (stage II) in a cohort of 60 patients with severe hemophilia without inhibitors. Results:The median age was 15.5 years (3 - 68). The ABR was 1.03 (62 episodes) in the first stage and 0.58 (35 episodes) in the second one, (p = 0.004). By type of bleeding, the impact of the intervention differs significantly in spontaneous bleeding (p = 0.007) and a 73% reduction in the first stage. There were no significant differences in traumatic bleeding. Conclusions: The use of pharmacokinetics for personalized dosing of patients with severe hemophilia A, significantly reduces ABR and spontaneous bleeding, improving the patient's quality of life and costs for the health system.
format	article
author	Samuel sarmiento Doncel Gina Alejandra Diaz Mosquera Javier Mauricio Cortes Nelson Ramirez Francisco Javier Meza Carol Agudelo Rico
author_facet	Samuel sarmiento Doncel Gina Alejandra Diaz Mosquera Javier Mauricio Cortes Nelson Ramirez Francisco Javier Meza Carol Agudelo Rico
author_sort	Samuel sarmiento Doncel
title	Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
title_short	Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
title_full	Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
title_fullStr	Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
title_full_unstemmed	Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
title_sort	impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia a in a personalized comprehensive management program
publisher	PAGEPress Publications
publishDate	2021
url	https://doaj.org/article/a5ae7a1c44ac4daba6f5389cbcdbe17d
work_keys_str_mv	AT samuelsarmientodoncel impactofpharmacokineticstoreducebleedinginacohortofpatientswithseverehemophiliaainapersonalizedcomprehensivemanagementprogram AT ginaalejandradiazmosquera impactofpharmacokineticstoreducebleedinginacohortofpatientswithseverehemophiliaainapersonalizedcomprehensivemanagementprogram AT javiermauriciocortes impactofpharmacokineticstoreducebleedinginacohortofpatientswithseverehemophiliaainapersonalizedcomprehensivemanagementprogram AT nelsonramirez impactofpharmacokineticstoreducebleedinginacohortofpatientswithseverehemophiliaainapersonalizedcomprehensivemanagementprogram AT franciscojaviermeza impactofpharmacokineticstoreducebleedinginacohortofpatientswithseverehemophiliaainapersonalizedcomprehensivemanagementprogram AT carolagudelorico impactofpharmacokineticstoreducebleedinginacohortofpatientswithseverehemophiliaainapersonalizedcomprehensivemanagementprogram
_version_	1718409309793026048

Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program

Ejemplares similares